NovoCure Limited Revenue
NovoCure Limited (NVCR) reported Revenue of $183.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-07-23
- NovoCure Limited revenues for the quarter ending 2026-06-30 was $183.58M, a 15.60% increase year-over-year.
- NovoCure Limited revenues for the quarter ending 2026-03-31 was $174.06M, a 12.30% increase year-over-year.
- NovoCure Limited revenues for the quarter ending 2025-12-31 was $174.35M, a 8.11% increase year-over-year.
- NovoCure Limited revenues for the quarter ending 2025-09-30 was $167.20M, a 7.81% increase year-over-year.
- NovoCure Limited revenues for fiscal 2024 was $605.22M, a 18.82% increase from fiscal 2023.
- NovoCure Limited revenues for fiscal 2023 was $509.34M, a 5.30% decline from fiscal 2022.
- NovoCure Limited revenues for fiscal 2022 was $537.84M, a 0.53% increase from fiscal 2021.
- NovoCure Limited revenues for fiscal 2021 was $535.03M, a 8.23% increase from fiscal 2020.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $183.58M 10-Q · filed 2026-07-23 | $357.64M 10-Q · filed 2026-07-23 | $531.99M derived: sum of 3 quarters · filed 2026-07-23 | $699.19M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $174.06M 10-Q · filed 2026-04-30 | $348.40M derived: sum of 2 quarters · filed 2026-07-23 | $515.61M derived: sum of 3 quarters · filed 2026-07-23 | $674.41M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $174.35M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-23 | $341.55M derived: sum of 2 quarters · filed 2026-07-23 | $500.36M derived: sum of 3 quarters · filed 2026-07-23 | $655.35M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $167.20M 10-Q · filed 2025-10-30 | $326.01M derived: sum of 2 quarters · filed 2026-07-23 | $481.00M 10-Q · filed 2025-10-30 | $642.27M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $158.81M 10-Q · filed 2026-07-23 | $313.80M 10-Q · filed 2026-07-23 | $475.06M derived: sum of 3 quarters · filed 2026-07-23 | $630.16M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $154.99M 10-Q · filed 2026-04-30 | $316.26M derived: sum of 2 quarters · filed 2026-04-30 | $471.36M derived: sum of 3 quarters · filed 2026-04-30 | $621.71M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $161.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $316.36M derived: sum of 2 quarters · filed 2026-02-26 | $466.72M derived: sum of 3 quarters · filed 2026-02-26 | $605.22M 10-K · filed 2026-02-26 |
| 2024-09-30 | $155.09M 10-Q · filed 2025-10-30 | $305.45M derived: sum of 2 quarters · filed 2025-10-30 | $443.95M 10-Q · filed 2025-10-30 | $577.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $150.36M 10-Q · filed 2025-07-24 | $288.86M 10-Q · filed 2025-07-24 | $422.64M derived: sum of 3 quarters · filed 2026-02-26 | $549.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $138.50M 10-Q · filed 2025-04-24 | $272.29M derived: sum of 2 quarters · filed 2026-02-26 | $399.61M derived: sum of 3 quarters · filed 2026-02-26 | $525.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $133.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $261.11M derived: sum of 2 quarters · filed 2026-02-26 | $387.16M derived: sum of 3 quarters · filed 2026-02-26 | $509.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | $127.32M 10-Q · filed 2024-10-30 | $253.37M derived: sum of 2 quarters · filed 2024-10-30 | $375.55M 10-Q · filed 2024-10-30 | $503.98M derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-06-30 | $126.05M 10-Q · filed 2024-07-25 | $248.23M 10-Q · filed 2024-07-25 | $376.66M derived: sum of 3 quarters · filed 2024-07-25 | $507.66M derived: sum of 4 quarters · filed 2024-07-25 |
| 2023-03-31 | $122.18M 10-Q · filed 2024-05-02 | $250.61M derived: sum of 2 quarters · filed 2024-05-02 | $381.61M derived: sum of 3 quarters · filed 2024-05-02 | $522.48M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $128.43M 10-K · filed 2023-02-23 | $259.43M derived: sum of 2 quarters · filed 2023-10-26 | $400.29M derived: sum of 3 quarters · filed 2023-10-26 | $537.84M 10-K · filed 2025-02-27 |
| 2022-09-30 | $131.00M 10-Q · filed 2023-10-26 | $271.86M derived: sum of 2 quarters · filed 2023-10-26 | $409.41M 10-Q · filed 2023-10-26 | $542.62M derived: sum of 4 quarters · filed 2023-10-26 |
| 2022-06-30 | $140.87M 10-Q · filed 2023-07-27 | $278.41M 10-Q · filed 2023-07-27 | $411.63M derived: sum of 3 quarters · filed 2023-07-27 | $545.23M derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-03-31 | $137.55M 10-Q · filed 2023-05-04 | $270.76M derived: sum of 2 quarters · filed 2023-05-04 | $404.37M derived: sum of 3 quarters · filed 2023-05-04 | $537.88M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $133.21M 10-K · filed 2023-02-23 | $266.82M derived: sum of 2 quarters · filed 2023-02-23 | $400.34M derived: sum of 3 quarters · filed 2023-02-23 | $535.03M 10-K · filed 2024-02-22 |
| 2021-09-30 | $133.61M 10-K · filed 2023-02-23 | $267.12M derived: sum of 2 quarters · filed 2023-02-23 | $401.82M 10-Q · filed 2022-10-27 | $545.77M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $133.52M 10-K · filed 2023-02-23 | $268.21M 10-Q · filed 2022-07-28 | $412.17M derived: sum of 3 quarters · filed 2023-02-23 | $544.83M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $134.69M 10-K · filed 2023-02-23 | $278.65M derived: sum of 2 quarters · filed 2023-02-23 | $411.31M derived: sum of 3 quarters · filed 2023-02-23 | $527.23M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $143.95M 10-K · filed 2023-02-23 | $276.61M derived: sum of 2 quarters · filed 2023-02-23 | $392.54M derived: sum of 3 quarters · filed 2023-02-23 | $494.37M 10-K · filed 2023-02-23 |
| 2020-09-30 | $132.66M 10-K · filed 2023-02-23 | $248.59M derived: sum of 2 quarters · filed 2023-02-23 | $350.41M 10-Q · filed 2021-10-28 | $449.65M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-06-30 | $115.92M 10-K · filed 2023-02-23 | $217.75M 10-Q · filed 2021-07-29 | $316.99M derived: sum of 3 quarters · filed 2023-02-23 | $409.05M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-03-31 | $101.83M 10-K · filed 2023-02-23 | $201.06M derived: sum of 2 quarters · filed 2023-02-23 | $293.12M derived: sum of 3 quarters · filed 2023-02-23 | $379.84M derived: sum of 4 quarters · filed 2023-02-23 |
| 2019-12-31 | $99.23M 10-K · filed 2022-02-24 | $191.30M derived: sum of 2 quarters · filed 2022-02-24 | $278.01M derived: sum of 3 quarters · filed 2022-02-24 | $351.32M 10-K · filed 2022-02-24 |
| 2019-09-30 | $92.06M 10-K · filed 2022-02-24 | $178.78M derived: sum of 2 quarters · filed 2022-02-24 | $252.08M 10-Q · filed 2020-10-29 | $321.76M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-06-30 | $86.71M 10-K · filed 2022-02-24 | $160.02M 10-Q/A · filed 2020-10-02 | $229.70M derived: sum of 3 quarters · filed 2022-02-24 | $294.45M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-03-31 | $73.31M 10-K · filed 2022-02-24 | $142.98M derived: sum of 2 quarters · filed 2022-02-24 | $207.74M derived: sum of 3 quarters · filed 2022-02-24 | $269.25M derived: sum of 4 quarters · filed 2022-02-24 |
| 2018-12-31 | $69.67M 10-K · filed 2021-02-25 | $134.43M derived: sum of 2 quarters · filed 2021-02-25 | $195.94M derived: sum of 3 quarters · filed 2021-02-25 | $248.07M 10-K · filed 2021-02-25 |
| 2018-09-30 | $64.76M 10-K · filed 2021-02-25 | $126.27M derived: sum of 2 quarters · filed 2021-02-25 | $178.40M 10-Q · filed 2019-10-31 | $232.06M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-06-30 | $61.51M 10-K · filed 2021-02-25 | $113.64M 10-Q · filed 2019-07-25 | $167.30M derived: sum of 3 quarters · filed 2021-02-25 | $217.41M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-03-31 | $52.13M 10-K · filed 2021-02-25 | $105.79M derived: sum of 2 quarters · filed 2021-02-25 | $155.90M derived: sum of 3 quarters · filed 2021-02-25 | $194.27M derived: sum of 4 quarters · filed 2021-02-25 |
| 2017-12-31 | $53.66M 10-K · filed 2020-02-27 | $103.77M derived: sum of 2 quarters · filed 2020-02-27 | $142.15M derived: sum of 3 quarters · filed 2020-02-27 | $177.03M 10-K · filed 2020-02-27 |
| 2017-09-30 | $50.11M 10-K · filed 2020-02-27 | $88.48M derived: sum of 2 quarters · filed 2020-02-27 | $123.36M 10-Q · filed 2018-10-25 | $153.61M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-06-30 | $38.38M 10-K · filed 2020-02-27 | $73.26M 10-Q · filed 2018-07-26 | $103.50M derived: sum of 3 quarters · filed 2020-02-27 | $125.17M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-03-31 | $34.88M 10-K · filed 2020-02-27 | $65.12M derived: sum of 2 quarters · filed 2020-02-27 | $86.80M derived: sum of 3 quarters · filed 2020-02-27 | $104.72M derived: sum of 4 quarters · filed 2020-02-27 |
| 2016-12-31 | $30.24M 10-K · filed 2019-02-28 | $51.92M derived: sum of 2 quarters · filed 2019-02-28 | $69.83M derived: sum of 3 quarters · filed 2019-02-28 | $82.89M 10-K · filed 2019-02-28 |
| 2016-09-30 | $21.67M 10-K · filed 2019-02-28 | $39.59M derived: sum of 2 quarters · filed 2019-02-28 | $52.65M derived: sum of 3 quarters · filed 2019-02-28 | |
| 2016-06-30 | $17.92M 10-K · filed 2019-02-28 | $30.97M derived: sum of 2 quarters · filed 2019-02-28 | ||
| 2016-03-31 | $13.05M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |